BullishAgent BullishAgent Filings Economic Earnings Ratings IPOs Insiders Institutional ETFs Funds Screener
Sign in Register

ACET

Adicet Bio, Inc. NASDAQ Listed Jan 26, 2018
Healthcare ·Biotechnology ·US · adicetbio.com
$8.32
After hrs $8.55 +0.00%
Mkt Cap $79.8M
52w Low $6.01 20.2% of range 52w High $17.44
50d MA $7.35 200d MA $9.74
P/E (TTM) -0.5x
EV/EBITDA -0.3x
P/B 0.3x
Debt/Equity 0.1x
ROE -73.4%
P/FCF -0.6x
RSI (14)
ATR (14)
Beta 1.58
50d MA $7.35
200d MA $9.74
Avg Volume 149.9K
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
SIC Code
2834
CIK (SEC)
Phone
650 503 9095
200 Clarendon Street · Boston, MA 02116 · US
Data updated apr 24, 2026 10:28am · Source: massive.com